REG - AstraZeneca PLC - AstraZeneca PLC - H1 2017 Results <Origin Href="QuoteRef">AZN.L</Origin> - Part 5

AstraZenecaAnnouncement

27/07/2017 07:07

- Part 5: For the preceding part double click  ID:nRSa2225Md 

n/m     15           50       50    
 FluMist/Fluenz       7            (95)     (94)    14           n/m      n/m     76           n/m      n/m     191          n/m      n/m   
 Others               385          12       16      375          (3)      1       361          (4)      2       379          5        2     
 Total Other          1,601        (25)     (24)    1,452        (9)      (7)     1,545        6        8       1,742        13       13    
                                                                                                                                            
 TOTAL PRODUCT SALES  5,748        (14)     (10)    5,836        2        3       5,850        -        1       6,207        6        7     
 
 
Shareholder Information 
 
 Announcement of nine months and third quarter 2017 results  9 November 2017                                                            
                                                                                                                                          
 Future dividends will normally be paid as follows:                                                                                     
 First interim                                               Announced with half-year and second-quarter results and paid in September  
 Second interim                                              Announced with full-year and fourth-quarter results and paid in March      
                                                                                                                                          
 
 
The record date for the first interim dividend for 2017, payable on 11 September 2017, will be 11 August 2017. Ordinary
Shares listed in London and Stockholm will trade ex-dividend from 10 August 2017. American Depositary Shares listed in New
York will trade ex-dividend from 9 August 2017. 
 
   
 
 
Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of
companies. Trademarks of companies other than AstraZeneca that appear in this document include Anticalin, a trademark of
Pieris AG; DuaklirGenuair, Duaklir, Eklira, and Tudorza, trademarks of Almirall, S.A.; Toprol-XL, a trademark of Aralez
Pharmaceuticals Inc. or AstraZeneca (depending on geography); Epanova, a trademark of Chrysalis Pharma AG.; Synagis, owned
by AstraZeneca or AbbVie Inc. (depending on geography); Kyntheum and Siliq, owned by Leo Pharma A/S or Valeant
Pharmaceuticals Luxembourg S.á.r.l. (depending on geography); and Zavicefta, a trademark of Pfizer Inc.; and Zomig, a
trademark of Grünenthal GmbH. 
 
 Addresses for Correspondence                                                            
 Registered Office1 Francis Crick AvenueCambridge Biomedical Campus, CambridgeCB2 0AAUK  Registrar andTransfer OfficeEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUK  Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSweden  US DepositaryCitibank Shareholder ServicesPO Box 43077ProvidenceRI 02940-3077USA                                     
 Tel: +44 (0)20 3749 5000                                                                Tel (freephone in UK):0800 389 1580 Tel (outside UK):                                             Tel: +46 (0)8 402 9000                                                                       Tel: (toll free in the US)+1 (888) 697 8018 Tel: (outside the US)+1 (781) 575 4555 citibank@shareholders-online.com  
                                                                                         +44 (0)121 415 7033                                                                                                                                                                                                                                                                                                 
 
 
Cautionary Statements Regarding Forward-Looking Statements 
 
_______________________________________________________________________________________ 
 
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act
1995, we are providing the following cautionary statement: 
 
This document contains certain forward-looking statements with respect to the operations, performance and financial
condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or
other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any
forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that
could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no
obligation to update these forward-looking statements. We identify the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could
cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond
our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or
trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP
rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any
failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with
manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay
to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and
acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic
competition; the impact of competition, price controls and price reductions; the risks associated with developing our
business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining
regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect
on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through
productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business
continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve
strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of
failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and
regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more
stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse
impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities;
the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of
failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social
medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this
presentation / webcast should be construed as a profit forecast. 
 
This information is provided by RNS
The company news service from the London Stock Exchange